Thursday, October 29, 2026, 1 PM-2 PM ET
Hear an expert discuss the evolving role of PD-L1 testing in HNSCC and ovarian cancer.
Webinar presenter Georgios Deftereos, MD, Professor of Pathology, Associate Director of the Clinical Cancer Genomics Laboratory, Director of Molecular Cytopathology, University of California, San Francisco
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Agilent.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 3, 2026, 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.
Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 10, 2026, 1 PM-2 PM ET
Join us for a session to help improve diagnostic accuracy in your practice when scoring HER2 IHC 0 with faint, incomplete membrane staining in ≤10% of tumor cells vs IHC 0 with no membrane staining detected in patients with mBC.
Webinar presenter Jeffrey Gregg, MD, University of Nevada
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.
Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Feb. 11, 2025—Ibex Medical Analytics has received FDA 510(k) clearance for Ibex Prostate Detect, an in vitro diagnostic, software only medical device that analyzes scanned histopathology whole slide images from prostate core needle biopsies prepared from H&E-stained formalin-fixed, paraffin-embedded tissue.
Feb. 10, 2025—Leica Biosystems announced the next iteration in its staining and coverslipping portfolio, the HistoCore Chromax Workstation.
Feb. 7, 2025—The FDA approved AstraZeneca and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) for the treatment of adult patients with unresectable or metastatic HR-positive, HER2-low (IHC 1+ or IHC 2+/ISH-) or HER2-ultralow (IHC 0 with membrane staining) breast cancer, as determined by an FDA-approved test, that has progressed on one or more endocrine therapies in the metastatic setting.
Feb. 3, 2025—The Food and Drug Administration approved a label expansion for the Roche Pathway anti-HER2/neu (4B5) Rabbit Monoclonal Primary Antibody to identify patients with hormone-receptor-positive, HER2-ultralow metastatic breast cancer who may be eligible for treatment with Enhertu.
Jan. 31, 2025—Genomadix announced it has received a medical device license from Health Canada permitting marketing of its Genomadix Cube CYP2C19 system, an automated sample-to-result PCR test.
Jan. 30, 2025—Roche announced that the Tina-quant Lipoprotein (a) Gen.2 Molarity assay has received 510(k) clearance from the FDA.
Jan. 28, 2025—Beckman Coulter Diagnostics announced the FDA has granted breakthrough device designation to the Access p‑Tau217/β-Amyloid 1-42 plasma ratio.
Jan. 22, 2025—Roche announced that the FDA has granted 510(k) clearance and CLIA waiver for its Cobas Liat sexually transmitted infection multiplex assay panels.
Jan. 21, 2025—Inflammatix announced that the FDA has granted marketing authorization for the TriVerity test system, a molecular test for patients with suspected acute infection or sepsis.
Jan. 17, 2025—Mayo Clinic announced the formation of Mayo Clinic Digital Pathology, designed on a platform architecture “to unlock the power of its archive of digital slides to revolutionize pathology and accelerate medical breakthroughs,” the organization said in its Jan. 13 press release.
